| BACKGROUND
Ulcerative colitis (UC) affects over 700 000 people in the United States. 1 For many patients with moderate to severe disease, the gutselective alpha-4-beta-7 integrin therapy, vedolizumab (VDZ), has proven effective, but is expensive and relatively slow to produce remission [2] [3] [4] Given the high cost of VDZ, insurers are often reluctant to pay for this therapy, which produces remission in roughly one-third of patients with UC in clinical trials. Patients treated with VDZ often do not respond immediately, and additional new clinical responses continue to accumulate even after 30 weeks of therapy. 5 This encourages physicians and patients to continue VDZ therapy at great expense in the hope of a late remission, though the likelihood of this outcome is low. Physicians, patients and insurers would like to be able to predict whether a given patient with UC will respond to VDZ at baseline, or at some early time point after starting therapy, rather than waiting up to 30 weeks (seven doses, or $43 782.76 in Average Wholesale Price drug costs) 6 to determine whether a satisfactory clinical response will occur.
With a pipeline of new therapies in IBD, 7 the growing number of treatment options for each patient raises the question of which therapy is most likely to work for each patient, and how long should we try a new, slow-acting therapy before switching drugs, increasing dose intensity, or adding a combination therapy. There is an increasing need to target therapies to the patients most likely to respond, given the high cost and growing number of therapeutic options in inflammatory bowel disease.
Leveraging clinical trial data may help elucidate which UC patients are most likely to benefit from each therapy, and make clinical decisions about starting or continuing therapies. The Clinical Study Data Request (CSDR) website 8 was implemented to provide researchers the opportunity to conduct further analysis with anonymised data from previously completed clinical studies.
Through the CSDR, we obtained access to the phase 3 patientlevel clinical trial data for the induction and maintenance of UC using VDZ. These data were used to predict whether baseline data, or data through week 6, could be predictive of week 52 corticosteroid-free endoscopic remission in UC patients treated with VDZ.
2 | ME TH ODS
| Overview
We obtained confirmation from our Institutional Review Board (IRB)
that IRB approval was not necessary to evaluate previously collected and de-identified clinical trial data from the CSDR for the phase 3 clinical trial data for the induction and maintenance of UC using VDZ (HUM00118527). Predictors and outcomes from the clinical trial dataset were used to develop and test predictive models of the outcome.
| Cohort and demographics
Our initial cohort consisted of 895 subjects. Subjects were excluded from model development if they were on placebo (N = 275), leaving 620 subjects. Additional subjects were excluded if they had missing predictor variables (N = 125) or were missing the outcome (N = 4). A final dataset of 491 de-identified subjects was used for modelling. Table 1 shows the demographics of the final cohort, as compared to the original cohort in the two arms that received VDZ. 
| Predictor variables

| Definition of outcomes
The primary outcome was corticosteroid-free endoscopic remission at week 52, defined by no use of corticosteroid medications (including prednisone and budesonide) at week 52, and a Mayo Sigmoidoscopy Score of 0 or 1 at week 52. Subjects without a visit at week 52, having a sigmoidoscopy score greater than 1, or using steroids (Prednisone EQ Dose or Budesonide EQ Dose > 0 at week 52)
were defined as failures. Patients who had a visit but who did not have a sigmoidoscopy score at week 52 were defined as a missing outcome, and were removed from the cohort (N = 4).
| Statistical analysis and model development
Random forest (RF) machine learning 9 was used to construct these algorithms. This method of prediction uses decision trees 9, 10 to classify a new observation. Each observation is run through each of the trees in the forest and each tree gives a classification (which can also be thought of as a vote). The forest combines the votes from all of the trees to compute a predicted score of the outcome. By choosing a value of the predicted score as a cut-off, one can obtain the desired balance of sensitivity and specificity for the outcome. We developed two random forest models using the predictor variables, one using only baseline data and one using data through week 6. To validate the predictive models, each dataset was split into a 70% training dataset for model development, and a 30% testing dataset.
This split method was preferred over an out-of-bag validation to show a true training and validation cohort, and to generate misclassification tables.
A baseline random forest model of 1000 trees with baseline variables was fit on the training set, and was used to produce the predictions on the test set. An additional week 6 random forest model of 1000 trees using cross sectional data at the final time point and longitudinal predictor variables was fit, the predictions tested on the test set, and the results compared across models.
| Training and testing cohorts
Training and testing datasets were derived by splitting the data randomly into 70% and 30% subsets. This was done 50 times, and the random forest model was fit on the training dataset and tested on the testing dataset each time. The AuROC (area under the receiver operating characteristic curve) values from the 50 replication test sets were averaged to obtain a mean AuROC. Subsequently, the one split of the 50 that produced an AuROC closest to the average AuROC for the week 6 model was selected as a representative split (training and testing cohorts) for both the week 6 and baseline models, which was used for ROC (receiver operating characteristic) plots, representative AuROCs, cut-off point selection, and misclassification tables. We then built baseline and week 6 random forest models on the entire dataset to have the most accurate models for future use, and we calculated variable importance and produced partial dependence plots based on these models.
| Model performance
The AuROC was used to evaluate the performance of each model.
All statistical analyses were performed using the statistical language R (version 3.3), using the packages randomForest, 9 and pROC. 
T A B L E 1 Subject demographics
The optimal cut-off was defined as the point on the ROC plot that is closest to the perfect point where both sensitivity and specificity are 1. In other words, we minimise the following criterion: (1-sensitivity) 2 + (1-specificity). 2 
| Variable importance
We evaluated the importance of predictors based on a random forest model built on the entire dataset. The relative importance of each predictor variable was determined by identifying nodes in the ensemble of trees in which the individual predictor variable appeared and summing the relative information content provided by all of the nodes containing that variable. Predictor variables that provided the greatest combined discrimination have higher importance.
| Partial dependence plots
Partial dependence plots were constructed to demonstrate how individual predictors can affect the probability of success, that is, corticosteroid-free endoscopic remission at week 52. For each predictor, we used the random forest model on the entire dataset to predict the probability of success for each patient with that predictor set to a given value, and averaged over all patients to produce a mean probability of success. We repeated this procedure for each value of that predictor in the data, or for its 50 quantiles if more than 50 values were available.
| Simpler pragmatic models
Given the complexity of these models, simpler models were considered more attractive for routine clinical use, if accurate. Informed by the Variable Importance Plots, we hypothesised that two simplified models for week 6 might be helpful, one with the week 6 faecal calprotectin alone, and the second using the FCP/VDZ level ratio at week 6. We also hypothesised that the baseline FCP might be helpful as a single predictor. We evaluated these single variable predictor models on the entire (100%) dataset to determine whether they could predict the week 52 corticosteroid-free endoscopic remission outcome.
| Reproducible research code repository
The code used to produce this analysis in R is available in a public within these two predicted classes are displayed in Figure 2A and Table 2 . True positives and true negatives are also displayed in Table 2 , which provides the sensitivity of 0.63 and specificity of 0.62.
| Effect of predictor variables at baseline
The effects of the predictors on the outcome of corticosteroid-free endoscopic remission at week 52 can be illustrated by partial dependence plots. Many of these are not linear. These are displayed in multiple panels in Figure S1 . Faecal calprotectin levels ≤811.5 lg/g at baseline predict success, and the rate of success increases steeply with lower FCP levels.
Lower uric acid levels, perhaps a marker of ongoing bowel damage and cell death, also predict higher rates of success with VDZ in UC. shown in Figure 3A and Table 2 . The P-value for the AuROC of the week 6 model vs. an AuROC of 0.5 is 1.23 9 10 À6 . The variable importance graph for the week 6 model is shown in Figure 3B . The five strongest predictors of corticosteroid-free endoscopic remission at week 52 were faecal calprotectin at week 6, the slope of VDZ level, the slope of FCP, albumin at week 6, and VDZ level at week 6. Notably weak predictors at week 6 for this outcome were the interval between VDZ doses, prior use of anti-TNF therapy, use of immunomodulators or corticosteroids at baseline, race and sex. The best cut-off, number of predicted successes and failures, and the proportion of subjects of true success within these two predicted classes are displayed in Table 2 and Figure 2B . This model classifies subjects into two groups: those likely to succeed (47%) and those likely to fail (53%). Those classified as likely to succeed achieve corticosteroid-free endoscopic remission in 58.6%, while those classified as likely to fail only achieve this outcome in 20.5%. The true positives and true negatives are also displayed in Table 2 , which provides the sensitivity of 0.72 and specificity of 0.68.
| Effect of predictor variables at week 6
The effects of the week 6 predictors on the outcome of corticosteroid-free endoscopic remission at week 52 can be illustrated in Figure S2 . Faecal calprotectin levels ≤233.67 lg/g at week 6 predict success, and the rate of success increases steeply with lower FCP levels. A significant fall in FCP between week 0 and week 6 (steeper negative slope) is a good prognostic marker. Lower albumin levels, perhaps a marker of chronicity and severity of ulcers, and colonic leak of VDZ, predict lower rates of success. As expected, higher VDZ levels predict success, but a falling VDZ level between week 2 and week 6 is a negative prognostic marker.
| Simpler pragmatic models
On the basis of the variable importance plots, we tested simpler models using a single predictor on the entire dataset, to see if sim- Table 2 . The true positives and true negatives are also displayed in Table 2 , which provides the sensitivity and specificity.
| DISCUSSION
Leveraging access to the GEMINI 1 clinical trial data 2 through the CSDR, we were able to apply machine learning tools to develop and validate predictive models of corticosteroid-free endoscopic remission in response to VDZ in UC. While the baseline model is relatively inaccurate, with a sensitivity of 63% and a specificity of 62%, it is helpful for clinicians to know that patients with a very elevated baseline faecal calprotectin (>811.5 lg/g) are at higher risk of VDZ failure. This study is limited to the data available from GEMINI 1, and is only as generalisable as these data which resulted in the FDA approval of VDZ for use in the treatment of UC.
Given the expense of biological therapies, being able to identify patients with a low rate of success after a short trial of therapy is valuable, as these patients can then move on to a different therapy, or a different mechanism of action in a timely fashion. This would reduce the time period of their active symptoms, likely reduce their exposure to steroids, and reduce the expense of a biological therapy that is likely to be futile in a given patient. This table presents the performance details for each model. The area under the receiver operating characteristic curve (AuROC) provides the discriminative power of each model. The best cut off for each model was based on the ROC plot to optimise the balance between the sensitivity and specificity. The number of cases predicted to be a success or failure is listed for each model, along with the respective true success rate, sensitivity and specificity.
ROC Plot for week 6 model Being able to identify UC patients who are at higher risk of failure with VDZ at baseline or at week 6 also provides an opportunity to improve the outcomes for these patients. Patients who are predicted as likely to fail VDZ might benefit from addition of a "booster" therapy after a model prediction of high risk of VDZ failure at week 6, possibly including an anti-TNF therapy, 12,13 a JAK inhibitor, 14 or an anti-IL23 therapy. 15 These severe UC patients, once they achieve low faecal calprotectin levels and adequate VDZ levels, may well be able to continue on VDZ maintenance monotherapy successfully. Future randomised clinical trials in this subset of patients are needed.
The limitations of this study include: (1) 224 of the 491 patients were already corticosteroid-free at baseline. However, to enter into the trial, subjects had to have active disease, defined by a Mayo score of at least 6 (with an endoscopy score of 2-3). Achieving steroid-free remission in these subjects is an important clinical endpoint, whether they started on steroids or not; (2) 
| CONCLUSION
A machine learning algorithm was able to distinguish IBD patients who are highly likely to achieve week 52 corticosteroid-free endoscopic remission with VDZ from those who are likely to fail VDZ using data collected by week 6 of therapy. A baseline model was numerically less accurate in predicting this outcome with VDZ. The ability to make early and accurate predictions of outcomes could help reduce costs by targeting this expensive therapy to the UC patients most likely to benefit, or could target additional interventions to patients who are likely to fail VDZ. While these algorithms are imperfect, they are arguably better than the current practice.
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